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Abstract
Purpose of review HIV-associated cryptococcal meningitis remains a significant public
health problem in parts of Africa and Asia and a major cause of AIDS-related mortality,
accounting for 15% of all AIDS-related deaths worldwide. Cryptococcal meningitis is
uniformly fatal if untreated, and access to antifungal therapy in regions with the highest
burden is often limited. Outcomes with fluconazole monotherapy are poor, and induction
treatment with amphotericin B and high-dose fluconazole for 2 weeks is associated with
significant drug-related toxicities and prolonged hospital admissions. This review focuses
on the potential of novel short-course and oral combination therapies for cryptococcal
meningitis.
Recent findings Recent clinical trials have shown that shorter courses of amphotericin, if
paired with oral flucytosine, rather than fluconazole, can achieve non-inferior mortality
outcomes. In addition, an oral combination of fluconazole and flucytosine is a potential
alternative. Liposomal amphotericin B may further simplify treatment; it is associated with
fewer drug-related toxicities, and a recent phase II randomised controlled trial demon-
strated that a single, high dose of liposomal amphotericin is non-inferior to 14 standard
daily doses at clearing Cryptococcus from cerebrospinal fluid. This has been taken forward
to an ongoing phase III, clinical endpoint study.
Summary The incidence and mortality associated with cryptococcal meningitis is still
unacceptably high. There is evidence supporting the use of short-course amphotericin B
and oral combination antifungal treatment regimens for cryptococcal meningitis (CM).
Ongoing research into short-course, high-dose treatment with liposomal amphotericin
may also help reduce the impact of this devastating disease.
Introduction
HIV-associated cryptococcal meningitis (CM) remains a
significant public health problem and a major cause of
AIDS-related mortality, despite increasing access to anti-
retroviral therapy (ART) [1, 2]. There are an estimated
220,000 cases each year, with the greatest burden of
disease found within resource-limited, high HIV preva-
lence settings. Across sub-Saharan Africa, CM remains
the most common cause of meningitis in adults living
with HIV [3]. As ART programmes were introduced, the
number of new cases fell, but in recent years, and despite
widened ART rollout, this number has plateaued with
CM being responsible for more than 180,000 annual
deaths and 15% of all AIDS-related mortality globally
[4•].
This review will focus on new approaches to the
treatment of CM, with a specific focus on the potential
of short-course or oral combination antifungal treat-
ment regimens in low- and middle-income countries
(LMICs). We outline the limitations of the currently
available treatment options, summarise recently pub-
lished research that has changed treatment guidelines,
and describe ongoing and future studies that may fur-
ther inform this approach. We then contextualise these
data and discuss current barriers to implementation that
need to be overcome, particularly regarding access to
medications in resource-limited settings.
The current treatment paradigm
Cryptococcal meningitis is uniformly fatal if left untreated [4•]. Treatment of
CM is challenging, requiring intensive antifungal therapy, the identification and
management of drug-related toxicities, strict control of raised intracranial pres-
sure, and the safe promotion of immune recovery with ART. The median CD4
count of individuals diagnosed with CM is approximately 30 cells/μL [5••], and
therefore, the management of these patients also involves the diagnosis and
treatment of other complications of advanced HIV disease.
The unacceptably high mortality associated with CM is driven, at least in
part, by the limited availability of effective antifungal medication in LMICs. The
most widely used oral antifungal treatment is fluconazole which is affordable,
widely available (often through donation), and has a good safety profile. When
given in high doses (800–1200 mg per day) as monotherapy for CM in a
clinical trial setting, fluconazole is associated with a 10-week mortality of 50–
60% [6, 7]. The limited efficacy of fluconazole when used in monotherapy is
attributed to its predominantly fungistatic activity, inhibiting growth of Crypto-
coccus to achieve a therapeutic effect, in contrast to other agents such as
amphotericin which are fungicidal. Fluconazole remains predominantly fungi-
static even at high doses; when maximally tolerated doses are given, clinical
failure rates remain high in comparison to other regimens [8]. In addition,
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fluconazole susceptibility in Cryptococcus species appears to be decreasing. A
systematic review in 2019 identified a rise in themedian fluconazoleminimum
inhibitory concentration (MIC) from4 μg/mL between 2000 and 2012 to 8 μg/
mL globally between 2014 and 2018 [9]. Similar findings were observed in
South Africa where the MICs of prospectively collected cryptococcal isolates
demonstrated a doubling of the geometric mean MIC between 2007 and 2008
and 2017 from 2.08 to 4.11 μg/mL [10]. Furthermore, a recent study demon-
strated that even in settings where primary genetic fluconazole resistance is rare,
poor fungal clearance occurs due to the phenomenon of heteroresistance: small
numbers of resistant subpopulations existing at levels low enough not to exert a
significant effect on the MIC but, in the presence of fluconazole alone, suscep-
tible subpopulations die and resistant clones dominate [11].
Given the marked limitations of fluconazole monotherapy, most interna-
tional guidelines for the management of CM in resource-limited settings have
recommended the addition of amphotericin B deoxycholate which, when
administered for 2 weeks alongside high-dose fluconazole, is associated with
roughly 30–40%mortality at 10 weeks [5••] in clinical trial settings. However,
amphotericin B is notoriously toxic, and induction treatment for 2 weeks is
commonly associated with thrombophlebitis, as well as an average drop in
haemoglobin of 2.3 g/dL and an increase in creatinine of 73% [12] (Fig. 1).
These toxicities require regular monitoring which may be difficult in settings
with limited healthcare workers and laboratory capacity. When comparing
outcome data from clinical trials with those collected through observational
Fig. 1. Individual data points and fitted locally weighted scatterplot smoothing curves for haemoglobin (left) and creatinine (right)
values over the first 14 days of antifungal therapy. (a) All patient receiving 14 days of amphotericin B based induction therapy. (b)
Plot by amphotericin B duration (short-course versus standard treatment). (c) Plot by sex. The broken lines indicate an anaemia
threshold of 6.5 g/dL (division of AIDS grade IV adverse event) and a creatinine of 220 μmol/L, indicating nephrotoxicity [12].
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studies, these challenges appear to translate to higher mortality rates in routine
care. Data collected from the national death registry in Botswana between 2012
and 2014, where amphotericin B and fluconazole was the standard of care,
identified a 10-week mortality of 50% [13]. In comparison, randomised con-
trolled trials of this regimen conducted in Vietnam and across multiple sites in
Africa have demonstrated lower mortality rates of 30–40% [5, 14]. Whilst
selection bias may influence the overall mortality rates in some clinical trials,
closer monitoring for toxicities and enhanced clinical care likely confer a
significant survival benefit.
The combination of 2 weeks of intravenous treatment alongside the associ-
ated toxicity means that managing a CM patient with this regimen involves a
minimumhospital stay of 14 days and regular blood tests. As a consequence, in
Uganda, the hospitalisation costs are approximately USD 560 [15]. In Zimba-
bwe, costs are approximately USD 800–1000 [16], and in South Africa, the cost
is estimated at USD 2453 [17]. Finally, amphotericin B must be refrigerated,
and the maintenance of a cold chain poses logistical challenges in resource-
limited settings.
Shorter-course amphotericin-based treatment
The major challenges of managing patients with two-week courses of
amphotericin B in low-resource settings have prompted investigation into
whether shorter courses could provide similar antifungal effects and reduce
the associated cost and toxicity. Data from animal models have paved the
way for future clinical trials. In particular, a 2013 study usingmurine and rabbit
models showed that 3 days of amphotericin B as induction therapy was as
effective as daily therapy for 14 days. These animal data also showed a
favourable pharmacokinetic profile of the abbreviated amphotericin B regimen,
with sustained antifungal activity and persistence in the CSF (Fig. 2) [18•].
Two phase II clinical studies, one conducted in Uganda [19] and another in
Malawi [7], both found participants treated with shorter courses of
amphotericin B had good clearance of Cryptococcus from the brain and
favourable side-effect profiles. The Ugandan study enrolled 30 HIV-infected
patients with first-episode CM and treated them for 5 days with amphotericin B
alongside 2 weeks of high-dose fluconazole. Repeat lumbar punctures were
performed on days 3, 7, and 14 to establish the early fungicidal activity (EFA),
a calculation of the mean rate of clearance of Cryptococcus from the CSF which
correlates with the clinical outcome. Although the study was underpowered to
detect any difference in mortality, it demonstrated mono-exponential fungal
clearance over the observed 14 days with the calculated EFA being the same at 7
(− 0.31 ± 0.14 log CFU/day) and 14 days (− 0.30 ± 0.11 log CFU/day), thereby
supporting the animal model data showing persistent antifungal effect after
cessation of amphotericin B. The Malawian study, through a two-step process,
randomised patients to one of four treatment arms: either 2 weeks of flucona-
zole monotherapy with or without amphotericin for 7 days or 2 weeks of
fluconazole and flucytosine with or without amphotericin for 7 days. Similar
to the Ugandan study, there was no reduction in EFA in the second week of
treatment after the course of amphotericin B had been completed. In addition,
when comparedwith historical cohorts treated with 2 weeks of amphotericin B,
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both of these studies found similar rates of EFA. The triple-combination treat-
ment arm in the Malawian study, containing fluconazole, amphotericin B, and
flucytosine, had a significantly higher EFA (− 0.50 ± 0.15 log CFU/day) than the
other treatment arms (amphotericin and fluconazole − 0.38 ± 0.19 log CFU/
Fig. 2. Effects of various regimens of amphotericin B for experimental cryptococcal meningoencephalitis in rabbits. Amphotericin B
at 1 mg/kg was administered daily (b), every third day (c), as an abbreviated regimen for 3 consecutive days (d), or once (e). The
solid arrows show the times of drug administration. The data in panels (a) to (e) represent the time course of infection in the CSF.
Each line represents the fungal burden in an individual rabbit. Panel (f) shows the fungal density in the cerebrum at the end of the
experiment. Each bar represents the mean fungal density ± the standard error of the mean. There is no statistically significant
difference in cerebral fungal density between rabbits that received daily therapy and those that received an abbreviated regimen of
1 mg/kg at 48, 72, and 96 h after inoculation. *, p = 1.00 (not significant); **, p = 0.006; ***, p G 0.001; ****, p G 0.001; *****,
p = 1.00 (not significant) [18•].
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day; fluconazole and flucytosine − 0.28 ± 0.17 log CFU/day) supporting the
rationale for phase III trials exploring both shorter-course amphotericin B
treatment and the role of flucytosine.
Flucytosine and the potential for oral combination therapy
In addition to the potential benefits of shorter-course amphotericin-based
regimens, the antifungal flucytosine has been tested both as an alternative
and in addition to fluconazole. Flucytosine’s effectiveness in combination
therapy was demonstrated in a 1997 trial showing flucytosine to increase the
rate of CSF sterilisation. In this study, 60% of patients receiving amphotericin B
and flucytosine had negative CSF cultures at 2 weeks compared to 51% of
patients treated with amphotericin alone [20]. Subsequent trials reiterated this
and also highlighted flucytosine as superior to fluconazole when used in
combination with amphotericin B. In a randomised controlled trial that recruit-
ed 299 participants in Vietnam, combination therapy with flucytosine was
shown to confer a survival benefit at 10 weeks when compared to amphotericin
alone (30% versus 44%; HR 0.61; 95%CI 0.39–0.97; p = 0.04). Despite a lower
absolute mortality rate, there was no statistically significant difference in mor-
tality when this arm was compared to amphotericin B given with fluconazole
(30% versus 33%; HR 0.87; 95% CI 0.53–1.42; p = 0.57) [14].
In the same Malawian study discussed above, flucytosine and fluconazole
combination therapy had a higher EFA than fluconazole alone [7]. A second
study inMalawi also found this effect on EFA in addition to improvedmortality
at 2 (10% versus 37%; HR 0.24; 95% CI 0.05–1.16; p = 0.05) and 10 weeks
(43% versus 58%;HR 0.59; 95%CI 0.25–1.44; p = 0.25) [21]. One benefit of an
oral combination antifungal treatment regimen is that it would not require any
daily intravenous infusion which would eliminate the risk of treatment-
associated thrombophlebitis. An oral treatment could also potentially reduce
the length of hospital admission, enabling milder or asymptomatic cases to
continue induction therapy at home and therefore reducing the costs associated
with CM. It is unlikely that this approach would ever obviate the need for
hospital admission as CM patients are often very unwell and can deteriorate
rapidly.
The ACTA study
A highly influential study in this field was the Antifungal Combinations for
Treatment of Cryptococcal Meningitis in Africa (ACTA) phase III randomised
controlled trial. This clinical endpoint trial recruited participants in southern,
eastern, and central Africa. HIV-infected patients with first-episode CM were
randomised to one of five arms: 2 weeks of amphotericin (1 mg/kg/day) with
either fluconazole (1200 mg/day) or flucytosine (100 mg/kg/day), 1 week of
amphotericin with either fluconazole or flucytosine, or oral combination ther-
apy with flucytosine and fluconazole. The trial recruited a total of 721 partici-
pants, and a pooled analysis of mortality at 10 weeks identified that, irrespec-
tive of partner drug, treatment for 7 days with amphotericin B was non-inferior
to treatment for 14 days (HR 0.89; 95% CI 0.66–1.21) (Fig. 3). Those
randomised to the arm receiving 7 days of amphotericin plus flucytosine
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experienced the lowest 10-weekmortality rate (24.2%)when comparedwith all
other regimes, including 2 weeks of amphotericin plus flucytosine (HR 0.56;
95% CI; 0.35–0.91; p = 0.001).
As a partner drug to amphotericin B, flucytosine performed better than
fluconazole (HR for death at 10 weeks with flucytosine vs. fluconazole 0.62;
95% CI 0.45–0.84; p = 0.002). All the flucytosine-containing regimens per-
formed better, with the data showing that fluconazole as a partner drug to
amphotericin Bwas associated with the highest 10-weekmortality: 48.6%when
given for 1 week (indicating that flucytosine is essential if short courses of
amphotericin are used) and 41.3% when given for 2 weeks of amphotericin
B. Despite having the slowest rate of clearance of cryptococcus from the CSF, the
oral combination arm was more effective in averting mortality than both of the
amphotericin B and fluconazole arms, and was the second best performing arm
with a 10-week mortality rate of 35% (95% CI 28.9–41.3%). This
amphotericin-sparing regimen was also associated with the smallest median
change in both haemoglobin (− 0.4 g/dL IQR − 1.0–0.4) and creatinine
(0 μmol/L IQR − 8.8–13.0).
Following the publication of the ACTA trial, a Cochrane review of treatment
for CM [22] analysed 13 clinical trials, most of which were conducted in
resource-limited settings. The review concluded that 1 week of amphotericin
B with flucytosine probably resulted in a lower risk of death within 10 weeks,
with shorter duration of amphotericin B therapy being associated with a lower
risk of life-threatening toxicities. Furthermore, the review highlighted that com-
bination oral therapy with flucytosine and fluconazole had a similar risk of
death compared to the traditional 2 weeks of amphotericin B and flucytosine.
Based on these findings, theWorldHealthOrganization updated their guidance
on the management of CM in a resource-limited setting to recommend 1 week
of amphotericin B with flucytosine as a first-line treatment in LMICs [23•]. In
Fig. 3. Kaplan-Meier curves from the ACTA study illustrating the all-cause mortality at 10 weeks according to treatment strategy.
The trial recruited a total of 721 participants, and mortality in the oral regimen, 1-week amphotericin B, and 2-week amphotericin B
groups was 35.1%, 36.2%, and 39.7% respectively. Irrespective of the partner drug, treatment with 7 days of amphotericin B was
non-inferior to treatment for 14 days (HR 0.89; 95% CI 0.66–1.21) [5••].
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addition, where amphotericin B is not available, the oral combination therapy
is recommended as a second-line regimen.
The role of liposomal amphotericin
The use of liposomal amphotericin (L-AmB, AmBisome, Gilead Sciences)
has the potential to further improve outcomes in the management of CM.
Despite being the mainstay of treatment in high-income settings [24, 25],
L-AmB has not been widely used in LMICs due to high costs. L-AmB is
however well-suited to short-course treatment of CM because high doses
can be safely administered owing to lower rates of drug toxicity than
amphotericin B, and because the drug has a long half-life in the brain
[26, 27]. Animal model studies have shown efficacy with higher doses of L-
AmB (10–20 mg/kg/day) [28, 29]. Studies to determine the shortest effec-
tive period of induction therapy with L-AmB in murine and rabbit models
used high-performance liquid chromatography to measure plasma and
brain concentrations of L-AmB, finding a dose-dependent decline in fungal
burden in the brain of mice, with a near-maximal efficacy achieved with L-
AmB at 10–20 mg/kg/day. Interestingly, the pharmacodynamics of a single
dose of 20 mg/kg was the same as that of 20 mg/kg/day given for 2 weeks
[29] (Fig. 4).
In addition, multiple human studies have also demonstrated safety
when administering higher doses of L-AmB for the treatment of visceral
leishmaniasis and invasive fungal infections in cancer patients [30]. A
randomised controlled trial conducted in India found that a higher dose
L-AmB (10 mg/kg) for the treatment of visceral leishmaniasis was not
associated with an increase in adverse effects when compared with
Fig. 4. The pharmacokinetics of liposomal amphotericin B in murine plasma (red) and cerebrum (black) in cohorts of mice infected
with Cryptococcus neoformans receiving 20 mg/kg single-dose intravenously. The terminal half-life in the plasma and cerebrum is
circa 133 h [28•].
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conventional therapy [31]. In this trial, a single dose of L-AmB (10 mg/kg)
was compared with amphotericin B (1 mg/kg administered every other day
for 29 days). The study demonstrated similar cure rates of 95.7% (95% CI
93.4–97.9) with L-AmB and 96.3% (95% CI 92.6–99.9) with conventional
amphotericin B. A similar dose has also been used in studies of stem cell
and liver transplant patients for antifungal prophylaxis, and both studies
showed the dose was well-tolerated [32, 33]. The potential benefits of
moving from daily intravenous amphotericin B to a single dose of L-
AmB include fewer drug-induced toxicities, a shorter hospital stay, and a
reduction in associated costs. In addition, L-AmB can be stored at an
ambient temperature which would simplify distribution and storage of
medication.
The AMBITION study
The AMBIsome Therapy Induction OptimisatiON (AMBITION) phase II
trial was an open-label randomised non-inferiority trial to compare
different short-course L-AmB regimens for the treatment of HIV-
associated CM [34••]. The study had four arms: (1) L-AmB 10 mg/kg/
day on day 1 (single dose), (2) L-AmB 10 mg/kg/day on day 1 and
5 mg/kg/day on day 3 (2 doses), (3) L-AmB 10 mg/kg/day on day 1 and
5 mg/kg/day on days 3 and 7 (3 doses), and (4) L-AmB 3 mg/kg/day for
14 days (control). All patients also received oral fluconazole 1200 mg/
day for 14 days. The primary endpoint was EFA and a total of 80
participants were recruited from sites in Botswana and Tanzania. The
study found that the EFA in all short-course regimens was comparable
to, or greater than, the control at the pre-defined non-inferiority margin.
There was no evidence for any dose-response effect with additional
doses. There were only 10 grade 3 and two grade 4 serious adverse
events that were attributed to study drugs. These included one grade 3
and one grade 4 anaemia which compared favourably to historical data
from 368 patients treated in Africa with amphotericin B where 33% of
patients reported a grade 3 or 4 anaemia [12]. Across all arms, the
median drop in haemoglobin over the 2-week induction period was
0.9 g/dL compared to a median drop of 2.3 g/dL observed with
amphotericin B [12]. Similarly, the percentage increase of baseline cre-
atinine was 14% compared to 73% with amphotericin B (Fig. 5). Final-
ly, the overall 10-week mortality was 29% which compared very
favourably with mortality rates recorded elsewhere in the literature [14,
35–37].
The single, high-dose regimen has been taken forward to a clinical endpoint
phase III trial which is currently recruiting participants from eight hospitals
across five countries in southern and eastern Africa [16]. The AMBITION phase
III trial will recruit 850 individuals with HIV-associated cryptococcal meningitis
and randomise them 1:1 to either (1) single-dose L-AmB (10 mg/kg) given
alongside 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/
day); or (2) 7 days of amphotericin B (1 mg/kg/day) given alongside 7 days of
flucytosine (100 mg/kg/day) and followed by 7 days of fluconazole (1200 mg/
day). The primary endpoint is all-cause mortality at 10 weeks. The trial
HIV-Associated Cryptococcal Meningitis: a Review of Therapies Moeng et al.
0
50
100
%
Ch
an
ge
in
Cr
ea
tin
in
e
Si
ng
le
D
os
e
Tw
o
D
os
es
Th
re
e
D
os
es
C
on
t r
ol
s
0
1
2
3
4
Ch
an
ge
in
Ha
em
og
lo
bi
n
g/
dL
L-
Am
B
Am
B-
d
14%
73%
0.9
g/dL
2.3
g/dL
a
b
Fig. 5. (a) The median percentage change from baseline creatinine and (b) the median drop in haemoglobin in all treatment arms
and each individual treatment arm in the AMBIsome Therapy Induction Optimisation (AMBITION) phase II trial [34••], compared
with a pooled analysis of 368 patients treated with amphotericin B [12].
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commenced recruitment in January 2018 and is expected to complete follow-up
in early 2021.
Cryptococcal antigen screening
Novel short-course and oral therapies for CM may also be relevant for the
management of cryptococcal antigenaemia. After individuals with advanced
HIV are exposed to Cryptococcus through respiratory inhalation, and usually
after a period of dormancy in the lungs, the organism enters the blood stream,
causing disseminated cryptococcal disease (cryptococcosis) before then
reaching end organs, most commonly the central nervous system [38].
Throughout the disease, Cryptococcus sheds its polysaccharide fungal capsule
which can be detected in the blood by highly sensitive and specific cryptococcal
antigen (CrAg) lateral flow assays [39, 40]. The prevalence of cryptococcal
antigenaemia among individuals with a CD4 count G 100 cells/μL is approxi-
mately 6.0–6.5% [41, 42], and among those with a CD4 count 101–200 cells/
μL is approximately 2.0% [42]. Cryptococcal antigenaemia has consistently
been shown to be highly predictive of death, most commonly due to the
development of CM, and the detection of CrAg in the blood provides an
opportunity to intervene and give preemptive treatment [43, 44]. CrAg screen-
ing programmes have therefore been adopted in many high HIV prevalence
settings. The current recommended initial treatment for cryptococcal
antigenaemia is fluconazole 1200 mg/day for 2 weeks [45••], and there is
consistent evidence that these programmes reduce the incidence of CM and
related mortality [46].
Despite this, there remains a persistent association between CrAg pos-
itivity and death, even among those who receive preemptive fluconazole
therapy [47–49]. This may be partially because some of these individuals
have symptomatic CM that has not been adequately investigated or be-
cause of subclinical CM which has been found to occur in 25–40% of
asymptomatic individuals with antigenaemia [50–52]. However, even for a
subset of the remaining patients who do not have CM, it is likely that
fluconazole is not adequate to prevent the development of CM. Given that
these individuals are often well and are managed as outpatients, there may
be a potential role for short-course intravenous or oral combination ther-
apy in preventing the development of CM. Randomised controlled data on
this subject are needed. A clinical trial exploring the potential role for a
single, high dose of L-AmB is currently underway in Uganda [53], and a
trial of oral combination therapy is also planned.
Implementation challenges
Despite the growing evidence to support both the use of flucytosine and
liposomal amphotericin in effective short-course and/or oral treatment
regimens for the treatment of CM in LMICs, there are significant implemen-
tation challenges to overcome before they can be widely used in the regions
of the world with the highest burden of HIV-associated CM [54].
Flucytosine was developed in 1957 and is no longer on patent but remains
expensive due tomonopoly pricing by a limited number ofmanufacturers [55].
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A 2-week treatment course in North America costs roughly 25,000 USD [56].
Flucytosine is alsomanufactured in Europe (Mylan, France) and costs 1.20USD
per tablet, meaning that a two-week treatment for a patient weighing 60 kg
costs 200 USD. An economic model using outcome data from the ACTA trial
found that, based on a price of 1.30 USD per tablet, the addition of 2 weeks of
flucytosine to fluconazole in settings where fluconazole monotherapy is the
mainstay of treatment would cost just 65 USD per life-year saved. Reducing the
cost of a single tablet to 0.80 USD and 0.40 USD would see this incremental
cost-effectiveness ratio reduce to 44 USD and 28 USD per life-year saved,
respectively [57].
Another barrier to the implementation of flucytosine therapy is that until
recently, it was not registered in any African countries. This is changing thanks to
the efforts of stakeholders in individual countries, the incorporation of
flucytosine into national treatment guidelines such as in South Africa [45••],
and internationally coordinated initiatives aiming to widen access to
flucytosine across countries with a high incidence of CM. In order to keep up
with this burgeoning demand, there is also a need to increase manufacturing
capacity.
Access to liposomal amphotericin is also impacted by the same eco-
nomic factors. A single vial costs between 80 USD and 400 USD, and a
single high-dose treatment for a patient weighing 60 kg requires 12 vials
[58]. In 2018, the manufacturers, Gilead Sciences, announced that vials of
AmBisome would become available at cost price as part of an expanded
access programme for CM in 116 LMICs [59], as is already the case for
visceral leishmaniasis. Dependent upon the results of the AMBITION trial,
an economic evaluation will be conducted to determine the cost-
effectiveness of giving a single high-dose [58].
Conclusion
The incidence and mortality associated with HIV-associated cryptococcal men-
ingitis is still unacceptably high, despite widened access to ART. This is in part
due to the suboptimal effects of fluconazole monotherapy, significant drug-
induced toxicities associated with amphotericin B, and limited access to supe-
rior treatments. The recently completed ACTA trial has provided evidence to
support the use of a short-course amphotericin B and oral combination anti-
fungal treatment regimens for CM, and the ongoing AMBITION trial hopes to
usher in a short-course, high-dose treatment with liposomal amphotericin.
Significant implementation challenges must be overcome to ensure that these
research findings contribute to a reduction in mortality from this devastating
disease.
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